pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·4h ago·1 min read
save

Medici wins Endpoints 2026 award, touts personalized cancer therapy

Sep 25, 2026·read at Endpoints ↗Positive

Medici was announced as the winner of the Endpoints 2026 competition.

The company said its approach focuses on tailoring cancer treatments to individual patients.

The award highlights growing interest in personalized oncology, though details of the technology were not provided.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Endpoints 11 2026 winner Medici believes the future of cancer therapy is personalized”

read at Endpoints ↗
85 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Oncology3

related stories

  • Apr 27Erasca reports RAS cancer drug data after legal threat from RevolutionEndpoints
  • Apr 27Revolution Medicines threatens to sue Erasca over patent, efficacy claimsEndpoints
  • Apr 27Lilly to buy startup Ajax in bid for a better JAK drugBioPharma Dive
  • Apr 27STAT+: Astellas retries XLMTM gene therapy after deathsSTAT
  • Apr 27Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitorEndpoints